Group 1 - The company held its fourth extraordinary general meeting of shareholders on September 15, 2025, with a total of 138 attendees representing 108,127,153 shares, accounting for 13.79% of the total shares [3][4] - All proposals presented at the meeting were approved, including amendments to the company's articles of association and internal governance systems [6][30] - The legal opinion provided by the attending lawyers confirmed that the meeting complied with relevant laws and regulations, and the resolutions made were valid [32] Group 2 - The company's stock experienced abnormal trading fluctuations, with a cumulative decline of over 12% in closing prices over three consecutive trading days from September 11 to September 15, 2025 [36] - The company confirmed that there were no undisclosed significant matters affecting stock prices, and previous disclosures were accurate [37][40] - The company is undergoing a pre-restructuring process initiated by creditors due to its inability to repay debts, with a restructuring investment agreement signed with Zhi'en Biotechnology Co., Ltd. [39][41]
2025年第四次临时股东会决议公告